Ametumumab
Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.Phase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 59/ 100
Competitive context
839 Active assets in the Colorectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
MARBLE DUST James Varani | Phase 2/3 | BB |
FLUOROURACILUM Washington University School of Medicine | Phase 4 | BB |
PANITUMUMAB M.D. Anderson Cancer Center | Phase 3 | BB |
Cetuximab Shanghai Henlius Biotech | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →